Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells

Journal of Clinical Investigation

Volumn 98, Issue 1, 1996, Pages 50-61

  Větvička, Václav ^a   Thornton, Brian P ^a   Ross, Gordon D ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

biological response modifiers; immunotherapy; integrins; monoclonal antibodies; neoplasms

Indexed keywords

BETA GLUCAN; BIOLOGICAL RESPONSE MODIFIER; CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT COMPONENT C3B; EPITOPE; INTEGRIN; LECTIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DEGRANULATION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LIGAND BINDING; NATURAL KILLER CELL; OPSONIZATION; PHAGOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST;

EID: 0030035119     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118777     Document Type: Article

References (89)

1. Taguchi, T., H. Furue, T. Kimura, T. Kondo, T. Hattori, and N. Ogawa. 1983. Clinical efficacy of lentinan on neoplastic diseases. Adv. Exp. Med. Biol. 166:181-187.
2. Aoki, T. 1984. Lentinan. In Immune Modulation Agents and Their Mechanisms. R.L. Fenichel and M.A. Chirigos, editors. Marcel Dekker, Inc. New York. 63-77.
3. Taguchi, T. 1987. Clinical efficacy of lentinan on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect. Prev. Suppl. 1:333-349.
4. Chihara. G. 1990. Lentinan and its related polysaccharides as host de-fense potentiators: their application to infectious diseases and cancer. In Immunotherapeutic Prospects of Infectious Diseases. K.N. Masihi and W. Lange, editors. Springer-Verlag, Berlin. 9-18.
5. Fujimoto, T., K. Omote, M. Mai, and S. Natsuume-Sakai. 1992. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer. Biotherapy. 5:153-163.
6. Oka, M., S. Yoshino, S. Hazama, K. Shimoda, and T. Suzuki. 1992. Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion. Biotherapy. 5:107-112.
7. Tari, K., I. Satake, K. Nakagomi, K. Ozawa, F. Oowada, Y. Higashi, T. Negishi, T. Yamada, H. Saito, and K. Yoshida. 1994. Effect of lentinan for advanced prostate carcinoma. Acta Urol. Jpn. 40:119-123.
8. Morikawa, K., R. Takeda, M. Yamazaki, and D. Mizuno. 1985. Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear β-1,3-D-glucan and other immunomodulators in murine cells. Cancer Res. 45:1496-1501.
9. Kasai, S., S. Fujimoto, K. Nitta, H. Baba, and T. Kummoto. 1991. Antitumor activity of polymorphonuclear leukocytes activated by a β-1,3-D-glucan. J. Pharmacobiodyn. 14:519-525.
10. Di Luzio, N.R., R. McNamee, E. Jones, J.A. Cook, and E.O. Hoffman. 1976. The employment of glucan and glucan activated macrophages in the enhancement of host resistance to malignancies in experimental animals. In The Macrophage in Neoplasia. M.A. Fink, editor. Academic Press. New York. 181-198.
11. Chen, J.-T. and K. Hasumi. 1993. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-γ. Biotherapy. 6:189-194.
12. Amino, M., R. Noguchi, J. Yata, J. Matsumura, R. Hirayama, O. Abe, K. Enomoto, and Y. Asato. 1983. Studies on the effect of lentinan on human immune system. II. In vivo effect on NK activity, MLR induced killer activity and PHA induced blastic response of lymphocytes in cancer patients. Jpn. J. Cancer Chemother. 10:2000-2006.
13. Di Renzo, L., E. Yefenof, and E. Klein. 1991. The function of human NK cells is enhanced by β-glucan, a ligand of CR3 (CD11b/CD18). Eur. J. Immunol. 21:1755-1758.
14. Tani, M., H. Tanimura, H. Yamaue, M. Iwahashi, T. Tsunoda, M. Tamai, K. Noguchi, and K. Arii. 1992. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. Eur. J. Clin. Pharmacol. 42:623-627.
15. Czop, J.K. 1986, The role of β-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol. Immunopathol. Res. 5:286-296.
16. Thornton, B.P., V. Větvička, M. Pitman, R.C. Goldman, and G.D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235-1246.
17. Ross, G.D. 1993. Membrane complement receptors. In Clinical Aspects of Immunology. P.J. Lachmann, D.K. Peters, F.S. Rosen, and M.J. Walport, editors. Blackwell Scientific Publications, Oxford. 241-264.
18. Smith, C.W. 1993. Leukocyte-endothelial cell interactions. Semin. Hematol. 30 (Suppl.) 4:45-55.
19. Springer, T.A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:301-314.
20. Hogg, N., and C. Berlin. 1995. Structure and function of adhesion receptors in leukocyte trafficking. Immunol. Today. 16:327-330.
21. Krych, M., J.P. Atkinson, and V.M. Holers. 1992. Complement receptors. Curr. Opin. Immunol. 4:8-13.
22. Zhou, M., R.F. Todd III, J.G.J. Van de Winkel, and H.R. Petty. 1993. Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fcγ receptor III on human neutrophils: possible role of lectin-like interactions. J. Immunol. 150:3030-3041.
23. Xue, W., A.L. Kindzelskii, R.F. Todd III, and H.R. Petty. 1994. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol. 152:4630-4641.
24. Stöckl, J., O. Majdic, W.F. Pickl, A. Rosenkranz, E. Prager, E. Gschwantler, and W. Knapp. 1995. Granulocyte activation via a binding site near the C-terminal region of complement receptor type 3 α-chain (CD11b) potentially involved in intramembrane complex formation with glycosylphosphatidylinositol-anchored FcγRIIIB (CD16) molecules. J. Immunol. 154:5452-5463.
25. Cao, D., I.F. Mizukami, B.A. Garni-Wagner, A.L. Kindzelskii, R.F. Todd III, L.A. Boxer, and H.R. Petty. 1995. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release: possible roles of complement receptor type 3 and calcium. J. Immunol. 154:1817-1829.
26. Gyetko, M.R., R.G. Sitrin, J.A. Fuller, R.F. Todd III, H. Petty, and T.J. Standiford. 1995. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J. Leukoc. Biol. 58:533-538.
27. Zarewych, D.M., A.L. Kindzelskii, R.F. Todd III, and H.R. Petty. 1996. LPS induces CD14 association with complement receptor type 3. which is reversed by neutrophil adhesion. J. Immunol. 156:430-433.
28. 3) for β-glucans. Complement Inflammation. 4:61-74.
29. Cain, J.A., S.L. Newman, and G.D. Ross. 1987. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement Inflammation. 4:75-86.
30. Sehgal, G., K. Zhang, R.F. Todd III, L.A. Boxer, and H.R. Petty. 1993. Lectin-like inhibition of immune complex receptor-mediated stimulation of neutrophils: effects on cytosolic calcium release and superoxide production. J. Immunol. 150:4571-4580.
31. Krauss, J.C., H. Poo, W. Xue, L. Mayo-Bond, R.F. Todd III. and H.R. Petty. 1994. Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fcγ receptor IIIB and the complement receptor type 3. J. Immunol 153:1769-1777.
32. Perlmann, P., H. Perlmann, and H.J. Müller-Eberhard. 1975. Cytolytic lymphocytic cells with complement receptor in human blood. Induction of cytolysis by IgG antibody but not by target cell-bound C3. J. Exp. Med. 141:287-296.
33. Perlmann, H., P. Perlmann, R.D. Schreiber, and H.J. Müller-Eberhard. 1981. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J. Exp. Med. 153:1592-1603.
34. Klein, E., L. Di Renzo, and E. Yefenof. 1990. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol. Immunol. 27:1343-1347.
35. Wright, S.D., and S.C. Silverstein. 1982. Tumor-promoting phorbol esters stimulate C3b and C3b′ receptor-mediated phagocytosis in cultured human monocytes. J. Exp. Med. 156:1149-1164.
36. Wright, S.D., and B.C. Meyer. 1986. Phorbol esters cause sequential activation and deactivation of complement receptors on polymorphonuclear leukocytes. J. Immunol. 136:1759-1764.
37. Roubey, R.A.S., G.D. Ross, J.T. Merrill, F. Walton, W. Reed, R.J. Winchester, and J.P. Buyon. 1991. Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18). J. Immunol. 146:3557-3562.
38. Ault, K.A., and T.A. Springer. 1981. Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells. J. Immunol. 126:359-364.
39. Breard, J., E.L. Reinherz, P.C. Kung, G. Goldstein, and S.F. Schlossman. 1980. A monoclonal antibody reactive with human peripheral blood monocytes. J. Immunol. 124:1943-1948.
40. Eddy, A., S.L. Newman, F. Cosio, T. LeBien, and A. Michael. 1984. The distribution of the CR3 receptor on human cells and tissue as revealed by a monoclonal antibody. Clin. Immunol. Immunopathol. 31:371-389.
41. Schulz, T.F., H. Scharfenberger, J.D. Lambris, P. Rieber, G. Riethmüller, and M.P. Dierich. 1985. Antigenic relationship between the alpha-chain of C3, a leukocyte-surface antigen involved in the activation of phagocytic cells, and a 50,000 MW B-cell antigen. Immunology. 54:791-800.
42. 3. J. Clin. Invest. 82:640-651.
43. Bayer, E.A., and M. Wilchek. 1980. The use of the avidin-biotin complex as a tool in molecular biology. Methods Biochem. Anal. 26:1-45.
44. Shevach, E.M. 1992. Immunofluorescence and cell sorting. In Current Protocols in Immunology. J.E. Colligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley and Sons, New York. 5.0.1-5.8.8.
45. Timonen, T., C.W. Reynolds, J.R. Ortaldo, and R.B. Herherman. 1982. Isolation of human and rat natural killer cells. J Immunol. Methods. 51:269-277.
46. O'Rear, L.D., and G.D. Ross. 1994. Assays for membrane complement receptors. In Current Protocols in Immunology, E.M. Shevach and J. Colligan, editors. John Wiley and Sons, New York. 13.14.1-13.4.18.
47. O'Rear, L.D., and G.D. Ross. 1994. Isolation of C3 from human plasma. In Current Protocols in Immunology. E.M. Shevach and J.E. Colligan, editors. John Wiley and Sons, New York. 13.3.1-13.3.16.
48. Buyon, J.P., S.B. Abramson, M.R. Philips, S.G. Slade, G.D. Ross, G. Weissmann, and R.J. Winchester. 1988. Dissociation between increased surface expression of gp165/95 and homotypic neutrophil aggregation. J. Immunol. 140: 3156-3160.
49. Ross, G.D., V. Větvička, and B.P. Thornton. 1996. Analysis of the phagocyte membrane lectin CR3 (CD11b/CD18) using fluorescence-labeled polysaccharides and flow cytometry. In Phagocyte Functions: A Guide for Research and Clinical Evaluation. J.P. Robinson and G. Babcock, editors. John Wiley and Sons, Inc. New York. In press.
50. Einspahr, K.J., R.T. Abraham, B.A. Binstadt, Y. Uehara, and P.J. Leibson. 1991. Tyrosine phosphorylation provides an early and requisite signal for the activation of natural killer cell cytotoxic function. Proc. Natl. Acad. Sci. USA. 88:6279-6283.
51. Gavioli, R., S. Spisani, A.L. Giuliani, E. Cosulich, A. Risso, and S. Traniello. 1991. CD16 and CR3 receptors distinguish between the two mechanisms of tumour cytotoxicity in neutrophils. Br. J. Haematol. 79:170-176.
52. Berger, M., J. O'Shea, A.S. Cross, T.M. Folks, T.M. Chused, E.J. Brown, and M.M. Frank. 1984. Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J. Clin. Invest. 74:1566-1571.
53. Kishimoto, T.K., M.A. Jutila, E.L. Berg, and E.C. Butcher. 1989. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science (Wash. DC). 245:1238-1241.
54. Neuman, E., J.W. Huleatt, and R.M. Jack. 1990. Granulocyte-macrophage colony-stimulating factor increases synthesis and expression of CR1 and CR3 by human peripheral blood neutrophils. J. Immunol. 145:3325-3332.
55. Limb, G.A., A.S. Hamblin, R.A. Wolstencroft, and D.C. Dumonde. 1991. Selective up-regulation of human granulocyte integrins and complement receptor 1 by cytokines. Immunology. 74:696-702.
56. Diamond, M.S., and T.A. Springer. 1993. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120:545-556.
57. Naccache, P.M., N. Jean, N.W. Liao, J.M. Bator, S.R. McColl, and P. Kubes. 1994. Regulation of stimulated integrin surface expression in human neutrophils by tyrosine phosphorylation. Blood 84:616-624.
58. 2+ binding epitope on leukocyte integrin a subunits. EMBO (Eur. Mol. Biol. Organ.) J. 8: 3759-3765.
59. Dransfield, I., C. Cabañas, A. Craig, and N. Hogg. 1992. Divalent cation regulation of the function of the leukocyte integrin LFA-1. J. Cell Biol. 116: 219-226.
60. Muto, S., V. Větvička, and G.D. Ross. 1993. CR3 (CD11b/CD18) expressed by cytotoxic T cells and NK cells is upregulated in a manner similar to neutrophils following stimulation with various activating agents. J. Clin. Immunol. 13:175-184.
61. Nauts, H.C., W.E. Swift, and B.L. Coley. 1946. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 6:205-216.
62. Bradner, W.T., D.A. Clarke, and C.C. Stock. 1958. Stimulation of host defense against experimental cancer. I. Zymosan and sarcoma 180 in mice. Cancer Res. 18:347-351.
63. Diller, I.C., Z.T. Mankowski, and M.E. Fisher. 1963. The effect of yeast polysaccharides on mouse tumors. Cancer Res. 23:201-208.
64. Komatsu, N., S. Okubo, S. Kikumoto, K. Kimura, G. Saito, and S. Sakai. 1969. Host-mediated antitumor action of schizophyllan, a glucan produced by Schizophyllum commune. Gann. 60:137-144.
65. Ramos, O.F., B. Nilsson, K. Nilsson, G. Eggertsen, E. Yefenof, and E. Klein. 1989. Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments. Cell. Immunol. 119:459-469.
66. Robinson, M.K., D. Andrew, H. Rosen, D. Brown, S. Ortlepp, P. Stephens, and E.C. Butcher, 1992. Antibody against the Leu-CAM β-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events. J Immunol. 148:1080-1085.
67. Pavlovic, M.D., M. Colic, N. Pejnovic, T. Tamatani, M. Miyasaka, and A. Dujic. 1994. A novel anti-rat CD18 monoclonal antibody triggers lymphocyte homotypic aggregation and granulocyte adhesion to plastic: different intracellular signaling pathways in resting versus activated thymocytes. Eur. J. Immunol. 24:1640-1648.
68. Ortlepp, S., P.E. Stephens, N. Hogg, C.G. Figdor, and M.K. Robinson. 1995. Antibodies that activate β2 integrins can generate different ligand binding states. Eur. J. Immunol. 25:637-643.
69. Sugie, K., K. Nakamura, K. Teshigawara, M.S. Diamond, T.A. Springer, Y. Nakamura, W.J. Leonard, A. Uchida, and J. Yodoi. 1995. Activation of natural killer cells by the mAb YTA-1 that recognizes leukocyte function-associated antigen-1. Int. Immunol. 7:763-769.
70. Sanguedolce, M.-V., C. Capo, M. Bouhamdan, P. Bongrand, C.-K. Huang, and J.-L. Mege. 1993. Zymosan-induced tyrosine phosphorylations in human monocytes: Role of protein kinase C. J. Immunol. 151:405-414.
71. 2 activation in murine macrophages. Biochim. Biophys. Acta Mol. Cell Res. 1222:265-276.
72. Zaffran, Y., J.C. Escallier, S. Ruta, C. Capo, and J.L. Mege. 1995. Zymosan-triggered association of tyrosine phosphoproteins and lyn kinase with cytoskeleton in human monocytes. J. Immunol. 154:3488-3497.
73. Berton, G., L. Fumagalli, C. Laudanna, and C. Sorio. 1994. β2 integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils. J. Cell Biol. 126:1111-1121.
74. Petty, H.R., and R.F. Todd III. 1993. Receptor-receptor interactions of complement receptor type 3 in neutrophil membranes. J. Leukocyte. Biol. 54: 492-494.
75. Zhou, M., D.M. Lublin, D.C. Link, and E.J. Brown. 1995. Distinct tyrosine kinase activation and Triton X-100 insolubility upon FcγRII or FcγRIIIB ligation in human polymorphonuclear leukocytes. Implication for immune complex activation of the respiratory burst. J. Biol. Chem. 270:13553-13560.
76. Bohuslav, J., V. Horejsí, C. Hansmann, J. Stöckl, U.H. Weidle, O. Majdic, I. Bartke, W. Knapp, and H. Stockinger. 1995. Urokinase plasminogen activator receptor, β2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1381-1390.
77. Williams, D.L., E.R. Sherwood, I.W. Browder, R.B. McNamee, E.L. Jones, and N.R. Di Luzio. 1988. Pre-clinical safety evaluation of soluble glucan. Int. J. Immunopharmacol. 10:405-414.
78. Pretus, H.A., H.E. Ensley, R.B. McNamee, E.L. Jones, I.W. Browder, and D.L. Williams. 1991. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J. Pharmacol. Exp. Ther. 257:500-510.
79. Chihara, G. 1992. Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Dev. Biol. Stand. 77:191-197.
80. Akimoto, M., T. Nishihira, and M. Kasai. 1986. Modulation of the antitumor effect of BRM under various nutritional or endocrine conditions. Jpn. J. Cancer Chemother. 13:1270-1276.
81. Suzuki, I., K. Hashimoto, S. Oikawa, K. Sato, M. Osawa, and T. Yadomae. 1989. Antitumor and immunomodulating activities of a β-glucan obtained from liquid-cultured Grifola frondosa. Chem. Pharm. Bull. 37:410-413.
82. Lotzová, E., and J.U. Gutterman. 1979. Effect of glucan on natural killer (NK) cells: further comparison between NK cell and bone marrow effector cell activities. J. Immunol. 123:607-611.
83. Maeda, Y.Y., M. Sakaizumi, K. Moriwaki, G. Chihara, and H. Yonekawa. 1992. Genetic control on lentinan-induced acute phase responses and vascular responses. Fol. Histochem. Cytobiol. 30:207-210.
84. Sato, Y., T. Sakai, T. Okada, Y. Sasano, T. Ando, J. Haruta, K. Kanayama, Y. Kuwahara, H. Tachino, and H. Tahara. 1990. A case of unresectable pancreatic cancer that responded to UFT chemotherapy. Gan. No. Rinsho. 36:2073-2078.
85. Yoshino, S., M. Oka, S. Hazama, and T. Suzuki. 1990. Effect of intrapleural and/or intraperitoneal lentinan therapy in carcinomatous pleuritis and peritonitis. Jpn. J. Cancer Chemother. 17:1588-1591.
86. Sakaguchi, T., Y. Watahiki, and A. Kosaka. 1993. A case of breast cancer with thrombosis during treatment of lung metastasis. Jpn. J. Cancer Chemother. 20:525-528.
87. Kotera, Y., J.D. Fontenot, G. Pecher, R.S. Metzgar, and O.J. Finn. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54:2856-2860.
88. Niculescu, F., H.G. Rus, M. Retegan, and R. Vlaicu. 1992. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140:1039-1043.
89. Ross, G.D., B.P. Thornton, and V. Větvička. 1995. Polysaccharide priming of CR3 (CD11b/CD18) allows NK cell killing of fresh breast tumor cells. The 9th Internatl. Cong. Immunol 95. (Abstr.)